Cipla strategy shift: FY26 India revenue tops ₹12,680cr

Why Cipla is recalibrating its growth engine

Pricing pressure and commoditisation in traditional generics are pushing Indian drugmakers to look for higher-value opportunities. Cipla is responding by stepping up its focus on differentiated respiratory products, chronic therapies, specialty medicines and complex generics. The company is leaning on a strong domestic franchise, a growing Africa business and an expanding specialty pipeline to drive the next phase of growth. The stated direction also reflects how Cipla’s revenue mix has been changing over the past few years.

India becomes a bigger anchor in the revenue mix

India now contributes nearly 45% of Cipla’s consolidated revenue, according to the provided material. The domestic business is increasingly driven by chronic therapies, consumer health products and trade generics, rather than acute therapies alone. Cipla’s India business crossed ₹12,680 crore in FY26, supported by double-digit growth in respiratory, anti-diabetes, urology and cardiac therapies. Within branded prescriptions, the chronic portfolio contributes more than 60% of the business. This shift matters because chronic therapies typically depend on sustained patient usage, which can reduce volatility compared with acute categories.

Respiratory remains core, with scale visible in key brands

Respiratory therapies continue to sit at the centre of Cipla’s strategy. Its respiratory brand Foracort crossed ₹1,000 crore in the Indian pharmaceutical market, showing the scale Cipla has built in the segment. In cardiac therapies, Dytor emerged as a ₹650-crore brand, highlighting that non-respiratory chronic categories are also adding meaningful size. During the year, Cipla introduced products across respiratory care, anti-diabetes, anti-microbial resistance, urology and dermatology. The launches cited include Voltido Trio Ciphaler, Empacip and Zemdri, with a focus on device-led therapies and differentiated treatments.

Partnerships and portfolio moves in FY26

Cipla used partnerships and acquisitions to widen its offerings during FY26. It secured rights from Eli Lilly to distribute Yurpeak in India, as per the provided text. It also partnered with MannKind to introduce inhaled insulin, expanded its neuro and CNS portfolio, and acquired a differentiated paediatrics and wellness business. Separately, Cipla has partnered with Eli Lilly to market tirzepatide in India as part of its near-term focus within cardiometabolic care. The company’s incoming managing director and global CEO-designate, Achin Gupta, said Cipla will prioritise tirzepatide for now while taking a cautious approach to the semaglutide branded-generics opportunity expected after the molecule goes off patent at the end of March.

Pipeline focus: complex respiratory, peptides and beyond oral generics

Cipla is advancing multiple respiratory, peptide and complex generic products, with several expected to be commercialised over FY27 and FY28. The pipeline mentioned includes oligonucleotide products, differentiated 505(b)(2) assets and biosimilars. The stated intent is to expand beyond conventional oral generics, which have been more exposed to price erosion. This direction is aligned with the broader trend of higher barriers to entry in complex products, including inhalation-led therapies where device know-how can matter.

Regulated-market catalyst: USFDA approval for Nintedanib capsules

On April 3, 2026, Cipla USA Inc announced final approval from the US Food and Drug Administration for its ANDA for Nintedanib Capsules, 100 mg and 150 mg. The product is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Cipla said its capsules are the generic therapeutic equivalent of Ofev, marketed by Boehringer Ingelheim. Marc Falkin, CEO of Cipla North America, said the approval strengthens the company’s respiratory franchise and reflects its commitment to delivering high-quality therapies to patients. Cipla added that the product will be available through appropriate pharmacy distribution channels, including specialty distribution.

South Africa and other emerging markets stay in the frame

The company reported expansion in South Africa’s prescription and over-the-counter businesses, supported by respiratory, CNS and metabolism therapies. In the same material, Cipla is described as focused on India, South Africa, North America, and key regulated and emerging markets. This footprint matters for execution because product strategies can vary by market, with different mixes of branded prescriptions, trade generics and tender-led demand.

Key numbers and milestones at a glance

What the shift signals for investors tracking Indian pharma

Cipla’s messaging indicates a deliberate push toward segments where differentiation can support pricing and durability. The domestic mix tilting toward chronic therapies, plus respiratory leadership anchored by large brands, shows where management believes sustainable demand sits. At the same time, the emphasis on complex generics, peptides, biosimilars and 505(b)(2) assets suggests a portfolio designed to compete in categories with higher technical and regulatory barriers. The USFDA approval for Nintedanib capsules adds a concrete regulated-market development tied to respiratory-focused capability.

Conclusion

Cipla is positioning its next phase of growth around differentiated respiratory products, chronic therapies, specialty medicines and complex generics, while using partnerships and targeted portfolio actions to broaden its addressable markets. With multiple products expected to be commercialised over FY27 and FY28, investors are likely to track execution milestones in the pipeline alongside the company’s efforts to deepen leadership in India and build global respiratory opportunities.